National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018

David Brieger, John Amerena, John R Attia, Beata Bajorek, Kim H Chan, Cia Connell, Ben Freedman, Caleb Ferguson, Tanya Hall, Haris M Haqqani, Jeroen Hendriks, Charlotte M Hespe, Joseph Hung, Jonathan M Kalman, Prashanthan Sanders, John Worthington, Tristan Yan and Nicholas A Zwar
Med J Aust 2018; 209 (8): . || doi: 10.5694/mja18.00646
Published online: 2 August 2018


Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are continually evolving and care for patients requires confidence in integrating these new developments into practice. These clinical practice guidelines will assist Australian practitioners in the diagnosis and management of adult patients with AF.

Main recommendations: These guidelines provide advice on the standardised assessment and management of patients with atrial fibrillation regarding:

  • screening, prevention and diagnostic work-up;
  • acute and chronic arrhythmia management with antiarrhythmic therapy and percutaneous and surgical ablative therapies;
  • stroke prevention and optimal use of anticoagulants; and
  • integrated multidisciplinary care.

Changes in management as a result of the guideline:

  • Opportunistic screening in the clinic or community is recommended for patients over 65 years of age.
  • The importance of deciding between a rate and rhythm control strategy at the time of diagnosis and periodically thereafter is highlighted. β-Blockers or non-dihydropyridine calcium channel antagonists remain the first line choice for acute and chronic rate control. Cardioversion remains first line choice for acute rhythm control when clinically indicated. Flecainide is preferable to amiodarone for acute and chronic rhythm control. Failure of rate or rhythm control should prompt consideration of percutaneous or surgical ablation.
  • The sexless CHA2DS2-VA score is recommended to assess stroke risk, which standardises thresholds across men and women; anticoagulation is not recommended for a score of 0, and is recommended for a score of ≥ 2. If anticoagulation is indicated, non-vitamin K oral anticoagulants are recommended in preference to warfarin.
  • An integrated care approach should be adopted, delivered by multidisciplinary teams, including patient education and the use of eHealth tools and resources where available. Regular monitoring and feedback of risk factor control, treatment adherence and persistence should occur.
  • David Brieger1
  • John Amerena2
  • John R Attia3,4
  • Beata Bajorek5
  • Kim H Chan6,7
  • Cia Connell8
  • Ben Freedman7
  • Caleb Ferguson9,10
  • Tanya Hall11
  • Haris M Haqqani12
  • Jeroen Hendriks13,14
  • Charlotte M Hespe15
  • Joseph Hung16
  • Jonathan M Kalman17,18
  • Prashanthan Sanders13,14
  • John Worthington6
  • Tristan Yan6
  • Nicholas A Zwar19

  • 1 Concord Repatriation General Hospital, Sydney, NSW
  • 2 University Hospital Geelong, Geelong, VIC
  • 3 University of Newcastle, Newcastle, NSW
  • 4 John Hunter Hospital, Newcastle, NSW
  • 5 UTS Sydney, Sydney, NSW
  • 6 Royal Prince Alfred Hospital, Sydney, NSW
  • 7 University of Sydney, Sydney, NSW
  • 8 National Heart Foundation of Australia, Melbourne, VIC
  • 9 Western Sydney University, Sydney, NSW
  • 10 Blacktown and Mount Druitt Hospital, Sydney, NSW
  • 11 Hearts4heart, Melbourne, VIC
  • 12 Prince Charles Hospital, Brisbane, QLD
  • 13 Royal Adelaide Hospital, Adelaide, SA
  • 14 University of Adelaide, Adelaide
  • 15 University of Notre Dame Australia, Sydney, NSW
  • 16 Sir Charles Gairdner Hospital, Perth, WA
  • 17 University of Melbourne, Melbourne, VIC
  • 18 Royal Melbourne Hospital, Melbourne, VIC
  • 19 University of Wollongong, Wollongong, NSW


Competing interests:

A full conflict of interest register is available at:


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.